Jul 9, 2026 07:47AM
Jun 17, 2026 09:00AM
Jun 17, 2026 09:00AM
May 12, 2026 09:00AM
Apr 23, 2026 09:01AM
Apr 23, 2026 09:00AM
Mar 31, 2026 04:05PM Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
Mar 31, 2026 05:19AM
Mar 30, 2026 07:01AM
Mar 30, 2026 07:01AM
Mar 30, 2026 07:00AM
Mar 30, 2026 07:00AM
Mar 17, 2026 10:01AM
Mar 10, 2026 09:00AM Connect Biopharma Phase 3 atopic dermatitis study to be presented at AAD
Mar 10, 2026 09:00AM
Mar 5, 2026 05:31PM
Feb 16, 2026 05:31PM
Jan 12, 2026 08:09AM
Jan 12, 2026 08:00AM
Nov 24, 2025 09:00AM
Nov 12, 2025 09:00AM Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Sep 29, 2025 09:00AM
Sep 4, 2025 08:00AM
Sep 3, 2025 08:03AM
Sep 3, 2025 08:00AM
Aug 27, 2025 09:00AM
Aug 14, 2025 08:00AM
Aug 13, 2025 09:00AM Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 22, 2025 09:15AM
Jul 22, 2025 09:00AM
Jul 21, 2025 09:02AM
Jul 21, 2025 09:00AM
Jul 18, 2025 09:00AM
Jul 9, 2025 09:02AM
Jul 9, 2025 09:00AM Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
Jun 13, 2025 09:01AM
Jun 13, 2025 09:00AM
May 28, 2025 09:00AM
May 20, 2025 09:00AM
May 15, 2025 09:00AM
May 14, 2025 09:00AM
May 13, 2025 09:08AM Connect Biopharma (CNTB) Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
May 13, 2025 09:00AM
Apr 24, 2025 09:00AM
Apr 11, 2025 09:00AM
Apr 1, 2025 09:02AM
Apr 1, 2025 09:00AM
Mar 31, 2025 04:05PM
Mar 31, 2025 04:05PM Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
Mar 31, 2025 09:00AM

326,538 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All